Fibromyalgia is frequently accompanied by autonomic nervous system dysfunction, often characterized by sympathetic predominance. Alterations in ocular microcirculation have been reported in the presence of autonomic dysfunction, including potential reductions in choroidal vascular parameters. This observational study aims to examine the association between autonomic symptom burden and the choroidal vascularity index (CVI), a quantitative marker of choroidal vascular structure derived from optical coherence tomography (OCT), in individuals with fibromyalgia compared with age- and sex-matched healthy controls.
Who can participate
Age range18 Years – 50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age 18-50 years, female or male
* Fibromyalgia group: diagnosis of fibromyalgia according to 2016 ACR criteria
* Ability and willingness to provide written informed consent
* Adequate ocular media clarity suitable for OCT imaging
* Control group: age- and sex-matched healthy volunteers
Exclusion Criteria:
* Ocular exclusions: cataract or other media opacity; glaucoma or optic nerve disease; ocular surface disorders (e.g., dry eye disease); retinal diseases (e.g., diabetic retinopathy, macular disease); ocular surgery or eye/head trauma within the last 3 months; best-corrected visual acuity \< 20/20; refractive error \> ±3.00 diopters; intraocular pressure \> 21 mmHg; use of topical ophthalmic medications
* Systemic/neurologic exclusions: diabetes mellitus; hypertension; hyperlipidemia; thyroid disorders; inflammatory rheumatic/autoimmune diseases; polyneuropathy or neurodegenerative disease; major depressive disorder or anxiety disorder; heavy smoking (\>20 cigarettes/day); alcohol or substance dependence; excessive caffeine intake (\>2.5 cups/day)
What they're measuring
1
Choroidal Vascularity Index (CVI)
Timeframe: Single assessment at study visit (baseline)
2
Autonomic Symptom Burden (COMPASS-31 total score)
Timeframe: Single assessment at study visit (baseline)
Trial details
NCT IDNCT07345546
SponsorProf. Dr. Cemil Tascıoglu Education and Research Hospital Organization